No Data
No Data
Jiangsu Hengrui Medicine Gets US FDA Approval for Anesthetic; Shares Rise 4%
The US Food and Drug Administration approved Jiangsu Hengrui Medicine's (SHA:600276) abbreviated new drug application for its bupivacaine liposome anesthetic injection, according to a Wednesday filing
Express News | Jiangsu Hengrui Pharmaceuticals Says It Gets U.S. FDA's Approval for Bupivacaine Liposome Injection
Jiangsu Hengrui Pharmaceuticals (600276.SH) has obtained FDA approval number in the USA.
On July 2nd, Gelunhui reported that Jiangsu Hengrui Pharmaceuticals Co., Ltd. (stock code:600276.SH) announced that the company has received a notice from the U.S. Food and Drug Administration (FDA) that the company's Bupivacaine Liposome Injectable Suspension ANDA application has been approved, becoming the first manufacturer to obtain approval for this type of generic drug in the United States. Bupivacaine is a widely used amide local anesthetic for local anesthesia and postoperative analgesia in clinical settings. Compared with the 5-6 hour duration of action of ordinary injectables, the analgesic effect of bupivacaine liposome injection can be extended for several days due to its advanced technology.
Jiangsu Hengrui Pharmaceuticals (600276.SH) has repurchased 0.04% of its shares.
Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that as of June 30, 2024, the company has repurchased 2,514,504 shares through centralized bidding trading, accounting for 0.04% of the total share capital. The highest transaction price was 40.77 yuan/share, the lowest was 39.00 yuan/share, and the total amount paid was 100,151,305.00 yuan (excluding transaction fees).
Jiangsu Hengrui Pharmaceuticals' subsidiary, HRS-7249 Injection, has been approved to conduct clinical trials for the treatment of hyperlipidemia.
Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that its subsidiary, Fujian Shengdi Pharmaceutical Co., Ltd., recently received the Notice of Clinical Trial Approval of Drugs from the National Medical Products Administration on HRS-7249 injection. After review, the clinical trial application for HRS-7249 injection accepted on April 2, 2024 meets the requirements for drug registration, and the clinical trial for the treatment of hyperlipidemia is approved. HRS-7249 injection is a type 1 innovative drug independently developed by the company. Non-clinical pharmacological studies have shown that HRS-7249 is effective in vivo.
Jiangsu Hengrui Pharmaceuticals (600276.SH) announced the buyback of 370,000 shares for the first time.
On June 20th, Gelunhui reported that on June 20th, 2024, Jiangsu Hengrui Pharmaceuticals (600276.SH) repurchased 370,000 shares through centralized bidding trading for the first time, and the repurchased shares accounted for 0.01% of the total share capital of the company. The highest transaction price was 40.77 yuan/share, the lowest price was 40.58 yuan/share, and the total amount paid was 15,045,277 yuan (excluding transaction fees).
No Data